Article Sidebar
Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Patient-centered pharmacovigilance: A review
Abstract
Purpose: To determine through a literature review, the current status of patients’ involvement in adverse drug reactions (ADRs) reporting.
Methods: Eighteen (18) studies which were published within the period from 2010 to 2016 were reviewed. The studies were extracted from seven databases, viz, Google Scholars, Medline, Academic Search Complete “EBSCO”, Health and Medical Complete ProQuest, Science Direct- Elsevier, SCOPUS and Wiley Online Library.
Results: The review revealed that although the reports by patients were of good quality, the patients’ awareness of, and attitude towards, ADR reporting were generally poor.
Conclusion: The results of this review suggest the need for patients’ enlightenment on ADRs reporting. Information on how to improve ADRs reporting is provided.
Keywords: Adverse drug reaction, Patients’ reporting; Systematic review, Patient-centered
pharmacovigilance
